miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in or...

Descripción completa

Detalles Bibliográficos
Autores principales: Merhautova, Jana, Hezova, Renata, Poprach, Alexandr, Kovarikova, Alena, Radova, Lenka, Svoboda, Marek, Vyzula, Rostislav, Demlova, Regina, Slaby, Ondrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433647/
https://www.ncbi.nlm.nih.gov/pubmed/26064968
http://dx.doi.org/10.1155/2015/941980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433647/
https://www.ncbi.nlm.nih.gov/pubmed/26064968
http://dx.doi.org/10.1155/2015/941980

Ejemplares similares